Production (Stage)
Structure Therapeutics Inc.
GPCR
$24.55
-$0.10-0.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.41% | 51.24% | 77.81% | 98.80% | 103.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.52% | 53.96% | 67.77% | 71.80% | 94.30% |
| Operating Income | -58.52% | -53.96% | -67.77% | -71.80% | -94.30% |
| Income Before Tax | -46.70% | -36.73% | -44.46% | -53.04% | -73.28% |
| Income Tax Expenses | 57.92% | 31.36% | -137.50% | 386.11% | 1,433.33% |
| Earnings from Continuing Operations | -46.73% | -36.72% | -43.59% | -53.23% | -73.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.73% | -36.72% | -43.59% | -53.23% | -73.76% |
| EBIT | -58.52% | -53.96% | -67.77% | -71.80% | -94.30% |
| EBITDA | -58.26% | -53.46% | -67.39% | -71.63% | -94.42% |
| EPS Basic | -10.97% | 7.82% | 60.04% | 74.32% | 82.19% |
| Normalized Basic EPS | -5.25% | 13.70% | 60.78% | 75.00% | 82.03% |
| EPS Diluted | -10.97% | 7.82% | 60.04% | 74.32% | 82.19% |
| Normalized Diluted EPS | -5.25% | 13.70% | 60.78% | 75.00% | 82.03% |
| Average Basic Shares Outstanding | 30.58% | 43.42% | 92.20% | 162.72% | 403.73% |
| Average Diluted Shares Outstanding | 30.58% | 43.42% | 92.20% | 162.72% | 403.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |